CLINICAL_TRIALS trial_result · 2026-08-13

Clinical Trial Results: A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) [Phase 3]

Phase 3 trial results for VRDN-001 in thyroid eye disease have been completed with safety and tolerability reported.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Viridian Therapeutics, Inc. | Conditions: Thyroid Eye Disease | Phase 3 | Status: COMPLETED | Results posted: 2026-08-13